21 CFR Parts 210/211
Every DSRV article whose Regulatory Snapshot cites 21 CFR Parts 210/211: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR Parts 210/211?
- 3 DSRV articles cite 21 CFR Parts 210/211. Enforcement cases behind them: FDA Warning Letters: Creative Essences (09/25/2025), SV Labs (12/09/2025), Patcos Cosmetics (03/12/2026); FDA Form 483 response practice and Warning Letter escalation patterns under 21 CFR Parts 210/211; Data-integrity (ALCOA+) and quality risk management expectations under 21 CFR Parts 210/211 and ICH Q9(R1), applied to AI-generated inputs. Inspection exposure across them: 2 high, 1 moderate.
- What does DSRV recommend for 21 CFR Parts 210/211?
- From the newest article (FDA’s 2025–2026 Warning-Letter Pattern: Water Systems Are Still Breaking Quality Systems, Not Just Utilities): When water-system excursions occur, treat them as quality-system governance events rather than isolated engineering work orders. DSRV is decision support, not legal advice; verify against the official source each article names.
- 6 min readHigh exposurecited as a tag
FDA’s 2025–2026 Warning-Letter Pattern: Water Systems Are Still Breaking Quality Systems, Not Just Utilities
If your water system is unstable, FDA is not just looking at maintenance. Recent warning letters show water-related failures treated as systemic failures in investigations, CAPA, product risk, and quality oversight.
- Case
- FDA Warning Letters: Creative Essences (09/25/2025), SV Labs (12/09/2025), Patcos Cosmetics (03/12/2026).
- DSRV take
- When water-system excursions occur, treat them as quality-system governance events rather than isolated engineering work orders.
- 7 min readHigh exposure
How to Respond to an FDA 483 Without Overcommitting
An FDA Form 483 lists inspectional observations, not final agency conclusions. The strongest responses are specific, evidence-led, and scoped — committing to what you can verifiably deliver rather than promising the world.
- Case
- FDA Form 483 response practice and Warning Letter escalation patterns under 21 CFR Parts 210/211.
- DSRV take
- A phased, evidence-backed commitment you can verifiably deliver beats a sweeping promise you will miss - the agency scores follow-through, not ambition.
- 7 min readModerate exposure
Why Generic AI Is Risky for Regulated Quality Decisions
General-purpose AI tools can sound authoritative while being wrong in ways that matter under GMP. We explain the specific failure modes — and what regulated quality work requires instead.
- Case
- Data-integrity (ALCOA+) and quality risk management expectations under 21 CFR Parts 210/211 and ICH Q9(R1), applied to AI-generated inputs.
- DSRV take
- Plausibility is not the GMP bar - an AI input that cannot show its sources, and may invent them, cannot underwrite a regulated decision.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR Parts 210/211. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.